

October 4, 2023

Merger of Wholly Owned Subsidiary

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, announced today a merger of its 100% owned subsidiary Yoshitomiyakuhin Corporation (Headquarters: Chuo-ku, Osaka; President and Representative Director: Shinichi Nakagawa; hereinafter, "Yoshitomiyakuhin"). The merger is expected to be completed by the end of March 2024.

Yoshitomiyakuhin was established in April 2000 as a promotional company specializing in prescription drugs for the psychiatric field and has been promoting products in that field including drugs manufactured and marketed by MTPC. Through this merger, MTPC will take over the track record and experience developed by Yoshitomiyakuhin in the field of psychiatry with the aim of further improve productivity and promote proper use of pharmaceuticals.

All rights and obligations related to promotion owned by Yoshitomiyakuhin will be transferred to MTPC. The Psychiatry Department (tentative name), which will be newly established within Sales and Marketing Division in April 2024, will be responsible for promotion of prescription drugs in the psychiatric area.

Mitsubishi Chemical Group has positioned medical as one of the focus markets in its management policy "Forging the Future". As the core company in the Mitsubishi Chemical Group's healthcare business, MTPC focuses on marketing pharmaceuticals for central nervous system disease, immuno-inflammation disease, diabetes and kidney diseases, and vaccines in Japan. Through this merger, MTPC will work to recreate its sales structure and deliver high-quality pharmaceutical information to healthcare professionals for realizing the MISSION of "Creating hope for all facing illness."

Contact:
Mitsubishi Chemical Group Corporation
Corporate Communications Division
Osaka Corporate Communications Department
+81-6-6205-5119

■ About YoshitomiyaKuhin Corporation

YoshitomiyaKuhin Corporation was established in April 2000 through the merger of three companies including the psychiatric division of Yoshitomi Pharmaceutical Industries, Ltd. As a promotion company specialized in the field of psychiatry, YoshitomiyaKuhin particularly handles a wide range of drugs manufactured and marketed by Mitsubishi Tanabe Pharma as well as drugs for the treatment of psychiatric disorders in collaboration with other pharmaceutical companies. YoshitomiyaKuhin conducts activities to communicate and collect information on prescription drugs according to treatment needs from university hospitals (psychiatry), general hospitals (psychiatry), psychiatric hospitals, and mental clinics throughout Japan.

YoshitomiyaKuhin Corporation website <https://www.yoshitomi.jp/>